Loading
MNPR-101 is an experimental radiolabelled humanised monoclonal antibody from Monopar Therapeutics, in phase 1 trials for advanced solid tumours expressing uPAR, bladder/urothelial cancer and triple-negative breast cancer and other cancers.
MNPR-101 is a radiolabelled humanised monoclonal antibody (imaging with zirconium-89; therapy with lutetium-177, actinium-225 preclinical) from Monopar Therapeutics. A humanised antibody against the urokinase plasminogen activator receptor (uPAR); labelled with zirconium-89 it is a PET imaging agent, and labelled with lutetium-177 (or actinium-225, preclinical) it delivers radiation to uPAR-expressing tumours. Its furthest stage is phase 1, for advanced solid tumours expressing uPAR, bladder/urothelial cancer, triple-negative breast cancer and lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. 10-K for 2025 (filed 27 March 2026): MNPR-101-Zr phase 1 imaging/dosimetry, MNPR-101-Lu phase 1a, MNPR-101-Ac late preclinical; FDA IND for MNPR-101-Lu cleared 26 September 2025. Registry: NCT06337084 and NCT06617169 active, not recruiting; expanded-access programmes NCT06980506 and NCT06980519 temporarily not available. Whether it works in people has not been established unless a trial below reports it.
A humanised antibody against the urokinase plasminogen activator receptor (uPAR); labelled with zirconium-89 it is a PET imaging agent, and labelled with lutetium-177 (or actinium-225, preclinical) it delivers radiation to uPAR-expressing tumours.
1.MNPR-101 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MNPR-101" OR ABSTRACT:"MNPR-101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MNPR-101, not a curated reading list.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Bladder & urothelial cancer, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Metastatic cancer (cancer that has spread), Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/